Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NANP | Q8TBE9 | 3/20 | 0.44 |
| ▸ | CD22 | P20273 | 5/20 | 0.43 |
| ▸ | SIGLEC7 | Q9Y286 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29326308 | 1.00 | NANP (0.44) | NANPCD22SIGLEC7 | |
| SCHEMBL24630028 | 0.95 | CD22 (0.43) | NANPCD22SIGLEC7 | |
| SCHEMBL29328805 | 0.91 | CD22 (0.52) | CD22 | |
| SCHEMBL24629737 | 0.91 | CD22 (0.52) | CD22 | |
| SCHEMBL24630013 | 0.91 | CD22 (0.52) | CD22 | |
| SCHEMBL29727710 | 0.91 | CD22 (0.52) | CD22 | |
| SCHEMBL31225445 | 0.87 | CD22 (0.49) | CD22 | |
| SCHEMBL29326365 | 0.83 | CD22 (0.47) | CD22SIGLEC7 | |
| SCHEMBL31225375 | 0.82 | CD22 (0.44) | NANPCD22 | |
| SCHEMBL24630006 | 0.81 | CD22 (0.41) | CD22 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240238422-A1 | Hypoimmunogenic Biotherapeutics | ADAXION THERAPEUTICS, INC. | 2024-07-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240238422-A1 | Hypoimmunogenic Biotherapeutics | FCGR3B, CD47, IL2 | NANP 1968/4885CD22 18/4885SIGLEC7 59/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.